Blog
RSS FeedPosted by Michael Wonder on 24 Jun 2020
Renibus Therapeutics receives FDA fast track designation for RBT-9 treatment in COVID-19
23 June 2020 - Renibus Therapeutics announced today that it has been granted fast track designation by the FDA for RBT-9 ...
Posted by Michael Wonder on 23 Jun 2020
Polynoma receives FDA fast track designation for its melanoma cancer vaccine seviprotimut-L
23 June 2020 - Polynoma announces that the U.S. FDA has granted its application for fast track designation of seviprotimut-L, ...
Posted by Michael Wonder on 18 Jun 2020
Linnaeus Therapeutics granted U.S. FDA fast track designation for LNS8801 for the treatment of patients with metastatic or unresectable melanoma who have progressed on anti-PD-1/L1 therapy
18 June 2020 - Company Conducting Ongoing Phase 1/2 Study of LNS8801. ...
Posted by Michael Wonder on 18 Jun 2020
Chi-Med announces fruquintinib granted U.S. FDA fast track designation for metastatic colorectal cancer
18 June 2020 - Hutchison China MediTech today announces that the U.S. FDA has granted fast track designation for the development ...
Posted by Michael Wonder on 17 Jun 2020
Ipsen receives FDA fast track designation for liposomal irinotecan (Onivyde) as a first-line combination treatment for metastatic pancreatic cancer
17 June 2020 - Final analysis of the Phase 1/2 clinical study to be presented as a late-breaking virtual presentation at ...
Posted by Michael Wonder on 13 Jun 2020
ZZ Biotech announces FDA fast track designation for stroke program
12 June 2020 - ZZ Biotech today announced that the US FDA has designated the investigation of the company’s experimental drug ...
Posted by Michael Wonder on 04 Jun 2020
TVAX Biomedical receives fast track designation from the FDA for brain cancer
4 June 2020 - TVAX Biomedical announced today receipt of fast track designation from the U.S. FDA for the use of ...
Posted by Michael Wonder on 28 May 2020
Cardiff Oncology announces fast track designation granted by the FDA to onvansertib for second-line treatment of KRAS mutated colorectal cancer
28 May 2020 - Fast Track designation for onvansertib in KRAS mutated metastatic colorectal cancer underscores the urgent need for new ...
Posted by Michael Wonder on 27 May 2020
Cellectar receives FDA fast track designation for CLR 131 in lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinaemia
26 May 2020 - Cellectar Biosciences today announced the U.S. FDA has granted fast track designation for CLR 131 in lymphoplasmacytic ...
Posted by Michael Wonder on 26 May 2020
Protara Therapeutics receives fast track designation from U.S. FDA for intravenous choline chloride for the treatment of intestinal failure associated liver disease
26 May 2020 - Protara Therapeutics today announced that the U.S. FDA has granted fast track designation to intravenous choline chloride ...
Posted by Michael Wonder on 23 May 2020
Orphazyme’s arimoclomol receives US fast track designation in amyotrophic lateral sclerosis
22 May 2020 - Orphazyme announces that the Company has received fast track designation from the US FDA for the development ...
Posted by Michael Wonder on 15 May 2020
Neuraptive Therapeutics announces FDA has granted fast track designation to NTX-001 clinical development program for treatment of patients with peripheral nerve injuries
14 May 2020 - Neuraptive Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation ...
Posted by Michael Wonder on 12 May 2020
Moderna receives FDA fast track designation for mRNA vaccine (mRNA-1273) against novel voronavirus
12 May 2020 - Finalizing protocol for Phase 3 study of mRNA-1273, expected to begin in early summer of 2020. ...
Posted by Michael Wonder on 08 May 2020
FDA grants fast track designation for omecamtiv mecarbil in heart failure
8 May 2020 - Fast track designation highlights the urgent need for new heart failure treatment options. ...
Posted by Michael Wonder on 07 May 2020
Ascentage Pharma's core drug candidate HQP1351 granted fast track designation by the US FDA, marking another milestone in its development
7 May 2020 - Ascentage Pharma today announced that the US FDA has granted HQP1351, the Company's core drug candidate, a ...